Focusing on a vital protein known to regulate synaptic plasticity and neuronal health enabled reactivation of dormant neural connections.

In clinical trials, PANXEON correctly identified 87 per cent of early-stage pancreatic cancers and caught precancerous conditions 64 per cent of the time, enabling earlier intervention